title: [Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-year tamoxifen treatment - a case report].
abstract: We report an 89-year-old patient with recurrent hormone-responsive breast cancer who presented with pleural, skin and bone metastases. Nineteen years previously, she had undergone a mastectomy and then for 16 years received adjuvant hormone therapy. The patient was orally administered a combination therapy of anastrozole, UFT and cyclophosphamide. A remarkable response was seen after 5 months, and no side effects were observed. The patient became well and the treatment was continued without relapse at 8 months. Oral anti-cancer treatments in combination with hormone therapy appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients.
authors.affiliation: Dept. of Surgery, Wakayama Medical University Kihoku Hospital.
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Sakurai
authors.forename: Teiji
authors.initials: T
authors.lastname: Umemura
authors.forename: Eri
authors.initials: E
authors.lastname: Jinta
authors.forename: Takaomi
authors.initials: T
authors.lastname: Suzuma
authors.forename: Goro
authors.initials: G
authors.lastname: Yoshimura
authors.forename: Sayuri
authors.initials: S
authors.lastname: Shimizu
authors.forename: Takeo
authors.initials: T
authors.lastname: Sakurai
mesh_terms: D000369:Aged, 80 and over; D000077384:Anastrozole; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use*; D010997:Pleural Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D011859:Radiography; D012008:Recurrence; D012878:Skin Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D013629:Tamoxifen / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use; D013997:Time Factors; D014230:Triazoles / Q000627:therapeutic use*; D014498:Uracil / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D005641:Tegafur; D000077384:Anastrozole; D014498:Uracil; D003520:Cyclophosphamide